Our Team
With over a century’s worth of experience amongst our members, the Hongsen Investment team is well versed and connected in all corners of the pharmaceutical industry. Coming from senior medical, research, and financial backgrounds, our team is driven by results and holds everything we do to the highest of standards.
Dr. Xu Ya Jun
Managing Partner
Dr. Xu is a co-founder of Epimab Biotherapeutics. Dr. Xu had held senior scientific positions at various global world-class pharmaceutical and healthcare companies including ChemPartner, Millennium Pharmaceutical and BASF/Abbott.
Dr. Xu holds Bachelor’s and Master’s degrees in Chemistry from the Beijing University of Chemical Technology, and a PhD in Biochemistry from Brandeis University. Dr. Xu had three years of Postdoctoral training at Harvard school of Public Health in department of Cell Biology, Endocrinology and Molecular Toxicology.
Mr. Benson Tsang
Managing Partner
Mr. Tsang was the Chief Financial Officer of WuXi Pharmatech Inc. and had led its IPO exercise in 2007, and was an Independent Director of ShangPharma Corp. Mr. Tsang also previously held senior positions at ATA (NASDAQ: ATAI), PCCW (0008:HK), Imation Corp., Coopers & Lybrand (HK) and Deloitte (Canada).
Mr. Tsang has over 30 years of experience in accounting, finance, merger & acquisition, business operations, company restructure, leading IPO and investor relations. He is currently an Independent Director of Athenex Inc. (NASDAQ: ATNX) and Pharmaron Beijing Co. Ltd. (3759.HK). Mr. Tsang is a member of HKCPA and CPA (Canada). He holds a Bachelor’s and an MBA from McMaster University.
Dr. Lo Yuk Lam
Partner
Professor Dr. Lo has made significant contributions to the advancement of science and technology in China. He brings three decades of experience in the biotech industry, corporate management, academic research and community service. His visionary leadership and patriotic enthusiasm have earned him respect throughout Hong Kong’s business and academic community.
Professor Dr. Lo is currently the Chairman of Food and Environmental Hygiene & Food and Health Bureau of HKSAR; Independent Director of Sinovac Biotech Ltd. (NASDAQ: SVA), Independent Non-Executive Director of Luye Pharma Group Limited (HKG:2186) and CSPC Pharmaceutical Group Limited (HKG:1093); President of HK Bio-Med Innotech Association; Chairman of GT Healthcare Capital Partners.
Professor Dr. Lo has served as President of Pacific Rim at PerkinElmer; President of Asia Pacific at Packard Bioscience and Managing Director of Asia Pacific at Bio-Rad Laboratories.
Mr. Michael Hui
Partner
Mr. Hui is a successful entrepreneur and investor and is a Managing Director of Pandect Bioventures. He also serves as Chairman and CEO of ShangPharma Holdings, Vice Chairman of Quantum Hi-Tech Biological, Chairman of Shanghai ChemPartner, and Chairman of ShangPharma Innovation.
Mr. Hui holds Bachelor’s and Master’s degrees in Chemistry from Oregon State University and Tulane University, respectively, and an MBA from the Stern School of Business of New York University.